August 1, 2012

• Obama Care contains implanted microchips

  I copied this from the Health Care Bill

  Subtitle C—National Medical
  10 Device Registry
  11 SEC. 2521. NATIONAL MEDICAL DEVICE REGISTRY.
  12 (a) REGISTRY.—
  13 (1) IN GENERAL.—Section 519 of the Federal
  14 Food, Drug, and Cosmetic Act (21 U.S.C. 360i) is
  15 amended—
  16 (A) by redesignating subsection (g) as sub-
  17 section (h); and
  18 (B) by inserting after subsection (f) the
  19 following:
  20 ‘‘National Medical Device Registry
  21 ‘‘(g)(1) The Secretary shall establish a national med-
  22 ical device registry (in this subsection referred to as the
  23 ‘registry’) to facilitate analysis of postmarket safety and
  24 outcomes data on each device that—
  25 ‘‘(A) is or has been used in or on a patient; and
  F:P11NHITRICOMMAAHCA09_001.XML
  f:VHLC7140971409.140.xml (444390|2)1002
  1 ‘‘(B) is—
  2 ‘‘(i) a class III device; or
  3 ‘‘(ii) a class II device that is implantable,
  4 life-supporting, or life-sustaining.
  5 ‘‘(2) In developing the registry, the Secretary shall,
  6 in consultation with the Commissioner of Food and Drugs,
  7 the Administrator of the Centers for Medicare & Medicaid
  8 Services, the head of the Office of the National Coordi-
  9 nator for Health Information Technology, and the Sec-
  10 retary of Veterans Affairs, determine the best methods
  11 for—
  12 ‘‘(A) including in the registry, in a manner con-
  13 sistent with subsection (f), appropriate information
  14 to identify each device described in paragraph (1) by
  15 type, model, and serial number or other unique iden-
  16 tifier;
  17 ‘‘(B) validating methods for analyzing patient
  18 safety and outcomes data from multiple sources and
  19 for linking such data with the information included
  20 in the registry as described in subparagraph (A), in-
  21 cluding, to the extent feasible, use of—
  22 ‘‘(i) data provided to the Secretary under
  23 other provisions of this chapter; and
  24 ‘‘(ii) information from public and private
  25 sources identified under paragraph (3);
  F:P11NHITRICOMMAAHCA09_001.XML
  f:VHLC7140971409.140.xml (444390|2)1003
  1 ‘‘(C) integrating the activities described in this
  2 subsection with—
  3 ‘‘(i) activities under paragraph (3) of sec-
  4 tion 505(k) (relating to active postmarket risk
  5 identification);
  6 ‘‘(ii) activities under paragraph (4) of sec-
  7 tion 505(k) (relating to advanced analysis of
  8 drug safety data); and
  9 ‘‘(iii) other postmarket device surveillance
  10 activities of the Secretary authorized by this
  11 chapter; and
  12 ‘‘(D) providing public access to the data and
  13 analysis collected or developed through the registry
  14 in a manner and form that protects patient privacy
  15 and proprietary information and is comprehensive,
  16 useful, and not misleading to patients, physicians,
  17 and scientists.
  18 ‘‘(3)(A) To facilitate analyses of postmarket safety
  19 and patient outcomes for devices described in paragraph
  20 (1), the Secretary shall, in collaboration with public, aca-
  21 demic, and private entities, develop methods to—
  22 ‘‘(i) obtain access to disparate sources of
  23 patient safety and outcomes data, including—
  24 ‘‘(I) Federal health-related electronic
  25 data (such as data from the Medicare proVerDate 
  F:P11NHITRICOMMAAHCA09_001.XML
  f:VHLC7140971409.140.xml (444390|2)1004
  1 gram under title XVIII of the Social Secu-
  2 rity Act or from the health systems of the
  3 Department of Veterans Affairs);
  4 ‘‘(II) private sector health-related
  5 electronic data (such as pharmaceutical
  6 purchase data and health insurance claims
  7 data); and
  8 ‘‘(III) other data as the Secretary
  9 deems necessary to permit postmarket as-
  10 sessment of device safety and effectiveness;

  • 10:21 am
  • 15 Comments